bsm-33053M [Primary Antibody]
AMACR Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Mouse

Target Protein: AMACR

Clonality: Monoclonal

Isotype: IgG

Entrez Gene: 23600

Swiss Prot: Q9UHK6

Source: KLH conjugated synthetic peptide derived from human AMACR

Purification: Purified by Protein G.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C for 12 months.

Background:

alpha-methylacyl-CoA racemase(AMACR/P504S) is Prostate-specific antigen (PSA) screening for prostate cancer is now widespread in the United States among men of all ages. However PSA has limited specificity because benign disease, including prostatic enlargement and inflammation, can increase PSA levels. Thus, a more specific prostate cancer markers is needed. One such potential marker is AMACR, an enzyme that is involved in peroxisomal beta-oxidation of dietary branched-chain fatty acids. Recent studies have shown that, compared with expression in normal or benign prostate epithelium, AMACR is consistently overexpressed in prostate cancer epithelium, making it a specific marker for cancer cells within the prostate gland. Furthermore, overexpression of AMACR may increase the risk of prostate cancer because its expression is increased in premalignant lesions (prostatic intraepithelial neoplasia).

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: MCF-7 cell lysates; Lane 2: Hela cell lysates probed with AMACR Monoclonal Antibody, Unconjugated (bsm-33053M) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


Lane 1: Mouse Kidney tissue lysates; Lane 2: Mouse Liver tissue lysates probed with AMACR Monoclonal Antibody, Unconjugated (bsm-33053M) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.